Cleared Traditional

Aventus Thrombectomy System (K251189) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2025
Decision
57d
Days
Class 2
Risk

K251189 is an FDA 510(k) clearance for the Aventus Thrombectomy System. Classified as Peripheral Mechanical Thrombectomy With Aspiration (product code QEW), Class II - Special Controls.

Submitted by Inquis Medical (Menlo Park, US). The FDA issued a Cleared decision on June 13, 2025 after a review of 57 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.5150 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Inquis Medical devices

Submission Details

510(k) Number K251189 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 17, 2025
Decision Date June 13, 2025
Days to Decision 57 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
68d faster than avg
Panel avg: 125d · This submission: 57d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code QEW Peripheral Mechanical Thrombectomy With Aspiration
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.5150
Definition To Mechanically Disrupt Thrombus And/or Debris Prior To Removal From The Peripheral Vasculature Through Aspiration.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. Clinical trial data may be submitted as supporting evidence to strengthen the substantial equivalence argument. Most Cardiovascular devices follow this clearance model.

Clinical Evidence

ClinicalTrials.gov
NCT05907564 Active not recruiting Interventional Industry-sponsored

Aventus Thrombectomy System Pulmonary Embolism Clinical Study

Evaluate the Safety and Efficacy of the Aventus Thrombectomy System for Aspiration Thrombectomy in Subjects With Acute Pulmonary Embolism

130
Patients (actual)
26
Sites
Treatment
Purpose
Open label
Masking
Condition studied Pulmonary Embolism; Embolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases
Study design Single group
Eligibility All sexes · 18 Years+
Principal investigator Jun Li, MD
Sponsor Inquis Medical, Inc. (industry)
Started 2023-09-20 Primary completion 2025-02-20 Completed 2026-10-01
Primary outcome
Change in RV/LV Ratio
View full study on ClinicalTrials.gov

Regulatory Peers - QEW Peripheral Mechanical Thrombectomy With Aspiration

All 118
Devices cleared under the same product code (QEW) and FDA review panel - the closest regulatory comparables to K251189.
Recana Thrombectomy Catheter System (FG014. FG015, FG016, FG017, FG018, FG019, FG020)
K251185 · Intervene · Oct 2025
INDIGO® Aspiration System – Lightning Flash Aspiration Tubing
K252612 · Penumbra, Inc. · Oct 2025
Symphony™ Thrombectomy System and Symphony™ 16F 82cm Thrombectomy System
K252057 · Imperative Care, Inc. · Aug 2025
Excipio LV Prime Thrombectomy Device
K251485 · Contego Medical, Inc. · Jun 2025
Liberant Thrombectomy System
K250787 · Medtronic, Ireland · Jun 2025
Symphony™ Thrombectomy System
K250775 · Imperative Care, Inc. · May 2025